
Two MRD reports in acute lymphoblastic leukaemia can appear to disagree when a family sees only a percentage or the words “detected” and “not detected”. The first question is whether they are measuring the same thing in comparable samples. A second opinion is more useful when the complete laboratory context is preserved than when different numbers are forced onto one home-made trend chart.
MRD means measurable, also called minimal, residual disease: small amounts of cancer that sensitive laboratory methods may detect during or after treatment. A negative result relates to the test’s capabilities and the material examined. It is not a stand-alone promise of cure. Equally, a positive finding does not by itself identify one inevitable next treatment.
In ALL, the result belongs alongside the exact disease findings and treatment received. Keep the original marrow and immunophenotyping reports, plus molecular results when performed. The reviewer needs to understand which initial finding was being followed and what the laboratory intended the later assay to measure.
For every report, record the sample date, sample type, method, full result and treatment time point. Keep comments about sensitivity, sample quality and interpretation. If a detail is missing, ask the existing laboratory or clinical team rather than borrowing an explanation from a different report found online.
Preserve marker names, units and original symbols in translations. A cropped photograph can remove the heading that gives a number its meaning. Keep the original document and translated copy together with matching dates. That allows the specialist to check unclear wording without assuming that apparently similar tests used the same technique.
“After treatment” is not a precise time point. Identify the course or phase that preceded sampling and the next decision under discussion. Add significant treatment interruptions and the treating clinician’s explanation. An early assessment and a later review can raise different questions even when both reports use the same abbreviation.
Information about MRD in AML should not be substituted for an ALL discussion. The separate article on the sequence of adult ALL treatment can help show where the report sits. The haematologist must interpret it within the complete diagnostic and clinical picture.
Ask whether the reports can reasonably be compared, which limitations matter and what the result changes in the proposed plan. If repeat testing is suggested, ask what uncertainty it would address and how its answer would influence a decision. Repeating a test in another country is not automatically more informative.
Do not interrupt prescribed therapy to obtain a supposedly clearer result. ALL needs timely specialist care, and new severe symptoms require local assessment without waiting for an overseas appointment. Arranging another opinion should run alongside ongoing treatment, according to a timetable agreed with the current team.
For a haematology consultation in Turkey, send complete MRD reports, original diagnostic records and a short treatment timeline. Tell Medicina Turkey which comparison needs explanation. The receiving specialist should confirm whether a new test is useful and which method is appropriate; a fixed test package is not the starting answer for every patient.
Medicina Turkey patient information. General guidance; individual medical decisions should be discussed with the treating clinician.
Choose whether Google Analytics and Google Ads may use optional cookies and measurement data. This panel controls Google measurement only; other site tools are not managed here. If you decline, Google may receive limited signals without cookies.
Your choice is remembered for up to 180 days and can be changed at any time. Personalised advertising stays off.